The Claim
RASSF1A down-regulation is correlated with tumor progression in adenocarcinoma and squamous cell lung cancer, with expression levels decreasing significantly from Stage I to Stage III.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In both adenocarcinoma and squamous cell lung cancer, lower levels of the RASSF1A protein are consistently observed as tumors advance from early to advanced stages.
See the scientific wording
RASSF1A down-regulation correlates with tumor progression in both adenocarcinoma and squamous cell lung cancer, with expression levels decreasing significantly as tumors advance from Stage I to Stage III.
In lung cancer, parts of chromosome 3 are deleted and the DNA around key genes gets chemically marked to shut them off. This turns off RASSF1A and two nearby genes that normally stop cells from dividing too fast. Without these genes, cells ignore signals to stop growing and keep dividing, allowing tumors to grow and spread from early to advanced stages.
What the research says
1 studyStudy: Solubilization and characterization of the κ-opioid receptor type from guinea-pig cerebellum
The study found that in most lung cancers, the RASSF1A gene is turned off, and the more the cancer has spread, the more likely this gene is suppressed — especially in adenocarcinoma. This matches the claim that RASSF1A gets weaker as the cancer gets worse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.